Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an ex...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Sobrero
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Sobrero1, J.-. Douillard2, F. Rivera3, F. Forget4, M. Karthaus5, M. Valladares-Ayerbes6, G. Demonty7, X. Guan8, M. Peeters9
  • 1IRCCS Ospedale San Martino IST, Genova, Italy, /
  • 2Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, St Herblain, France, /
  • 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 4Centre Hospitalier de l'Ardenne, Libramont, Luxembourg, /
  • 5Städtisches Klinikum München, Klinikum Neuperlach, Munich, Germany, /
  • 6Virgen del Rocio Hospital, IBIS Institute for Biomedicina of Seville, Seville, Spain, /
  • 7Amgen (Europe) GmbH, Zug, Switzerland, /
  • 8Amgen Inc., Thousand Oaks, California, USA, /
  • 9Antwerp University Hospital, Edegem, Belgium, /


Biologic therapies such as epidermal growth factor receptor inhibitors (EGFRi) and vascular endothelial growth factor inhibitors (VEGFi) improve clinical outcomes of patients with RAS WT mCRC when added to first-line chemotherapy, compared with chemotherapy alone. Preclinical data suggest that the sequence of therapy may be important in terms of tumour biology, but optimal sequencing of targeted therapies has not been determined in a phase III prospective clinical trial. Here we report an exploratory analysis of OS for patients with RAS WT mCRC treated with either first-line panitumumab and second-line VEGFi therapy, or first-line bevacizumab and second-line EGFRi.